Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736270 | 0.85 | HTR1A (0.36) | SIGMAR1OPRM1ADRA1AROCK2 | |
| SCHEMBL735835 | 0.81 | NPY5R (0.47) | MEN1KMT2ASIGMAR1OPRM1OPRL1 | |
| SCHEMBL737442 | 0.81 | SIGMAR1 (0.62) | MEN1KMT2ASIGMAR1OPRM1KCNH2 | |
| SCHEMBL736873 | 0.78 | SIGMAR1 (0.47) | SIGMAR1OPRM1KCNH2NPY5RROCK2 | |
| SCHEMBL735827 | 0.78 | SIGMAR1 (0.42) | SIGMAR1OPRM1HTR6ADRA1AROCK2 | |
| SCHEMBL18735596 | 0.78 | MEN1 (0.42) | MEN1KMT2ASIGMAR1OPRM1OPRL1 | |
| SCHEMBL17319026 | 0.78 | MEN1 (0.39) | MEN1KMT2ASIGMAR1OPRM1OPRL1 | |
| SCHEMBL737501 | 0.77 | SIGMAR1 (0.45) | MEN1KMT2ASIGMAR1OPRM1KCNH2 | |
| SCHEMBL736048 | 0.77 | SIGMAR1 (0.46) | MEN1KMT2ASIGMAR1OPRM1OPRL1 | |
| SCHEMBL17319028 | 0.77 | SIGMAR1 (0.74) | SIGMAR1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | MEN1 2420/4885KMT2A 825/4885SIGMAR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.